WO2008125366A3 - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases Download PDF

Info

Publication number
WO2008125366A3
WO2008125366A3 PCT/EP2008/004992 EP2008004992W WO2008125366A3 WO 2008125366 A3 WO2008125366 A3 WO 2008125366A3 EP 2008004992 W EP2008004992 W EP 2008004992W WO 2008125366 A3 WO2008125366 A3 WO 2008125366A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
substance
ebv
cidal
involve
Prior art date
Application number
PCT/EP2008/004992
Other languages
French (fr)
Other versions
WO2008125366A2 (en
Inventor
Francesca Aloisi
Barbara Serafini
Original Assignee
Ist Superiore Sanita
Francesca Aloisi
Barbara Serafini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Superiore Sanita, Francesca Aloisi, Barbara Serafini filed Critical Ist Superiore Sanita
Publication of WO2008125366A2 publication Critical patent/WO2008125366A2/en
Publication of WO2008125366A3 publication Critical patent/WO2008125366A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Aberrant infection of B cells by (Epstein-Barr virus) EBV leads to autoimmune disease, especially multiple sclerosis, myasthenia gravis and Hashimoto's thyroiditis, and can be treated or immunised against. Treatment may involve an anti-EBV substance such as acyclovir, valacyclovir, interferon, antibodies or SIRNA. Treatment may also involve a B-cell cidal substance such as Rituximab and/or a T-cell inhibitory/cidal substance. Also disclosed is a vaccine for preventing autoimmune disease comrising an EBV epitope.
PCT/EP2008/004992 2007-04-13 2008-04-11 Treatment of autoimmune diseases WO2008125366A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0707208.5 2007-04-13
GBGB0707208.5A GB0707208D0 (en) 2007-04-13 2007-04-13 Novel disease treatments

Publications (2)

Publication Number Publication Date
WO2008125366A2 WO2008125366A2 (en) 2008-10-23
WO2008125366A3 true WO2008125366A3 (en) 2009-07-16

Family

ID=38116725

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004992 WO2008125366A2 (en) 2007-04-13 2008-04-11 Treatment of autoimmune diseases

Country Status (2)

Country Link
GB (1) GB0707208D0 (en)
WO (1) WO2008125366A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9631243B2 (en) * 2012-06-18 2017-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for identifying JC virus
US9617607B2 (en) 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
WO2014110127A1 (en) 2013-01-08 2014-07-17 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
ITRM20130206A1 (en) 2013-04-05 2014-10-06 Univ Roma GENOTYPE VERSIONS OF EPSTEIN BARR VIRUSES AND THEIR USES AS POSSIBLE RISK PREDICTORS, THERAPEUTIC BIOMARKERS AND TARGETS IN MULTIPLE SCLEROSIS
WO2022146869A1 (en) * 2020-12-29 2022-07-07 The Board Of Trustees Of The Leland Stanford Junior University Diagnostics and therapeutics for ebv in ms and other autoimmune diseases

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
WO1989006968A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
EP0501233A1 (en) * 1991-02-26 1992-09-02 Bayer Corporation Hybridomas and monoclonal antibodies that inhibit anti-CD3-stimulated T cell proliferation
WO1993004695A1 (en) * 1991-08-28 1993-03-18 The Wistar Institute T cell receptor-based therapy for rheumatoid arthritis
IL89953A (en) * 1989-02-03 1994-04-12 Xoma Corp Pharmaceutical composition comprising anti-t cell immunotoxin for use in treating autoimmune disease
WO1998030586A2 (en) * 1997-01-13 1998-07-16 Oklahoma Medical Research Foundation Diagnostics and therapy of epstein-barr virus in autoimmune disorders
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
WO2000067796A1 (en) * 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
WO2001037868A1 (en) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
WO2001058481A2 (en) * 2000-02-09 2001-08-16 Oklahoma Medical Research Foundation Diagnostics and therapy of epstein-barr virus in autoimmune disorders
WO2002047720A2 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders
WO2003025541A2 (en) * 2001-09-18 2003-03-27 Chiron Corporation Methods for treating multiple sclerosis
WO2003028753A1 (en) * 2001-09-29 2003-04-10 Andreas Schwarting USE OF INTERFERON β IN THE THERAPY OF SYSTEMIC LUPUS ERYTHEMATODES
WO2003045978A2 (en) * 2001-11-26 2003-06-05 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20030148963A1 (en) * 2000-05-31 2003-08-07 Andrej Tarkowski Use of etoposide
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
WO2004004798A2 (en) * 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
WO2004032828A2 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20040151694A1 (en) * 1994-04-12 2004-08-05 Staley Brod Method of treating auto-immune diseases using type one interferons
WO2005009466A1 (en) * 2003-07-24 2005-02-03 Universita' Degli Studi Di Perugia Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
WO2005117978A2 (en) * 2004-06-04 2005-12-15 Genentech, Inc. Method for treating multiple sclerosis
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
WO2006076651A2 (en) * 2005-01-13 2006-07-20 Genentech, Inc. Treatment method
US20060240008A1 (en) * 2003-04-09 2006-10-26 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
US20060257363A1 (en) * 2004-03-10 2006-11-16 Pepgen Corporation Treatment using an interferon
WO2007014238A2 (en) * 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules

Patent Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
WO1989006968A1 (en) * 1988-02-03 1989-08-10 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
IL89953A (en) * 1989-02-03 1994-04-12 Xoma Corp Pharmaceutical composition comprising anti-t cell immunotoxin for use in treating autoimmune disease
EP0501233A1 (en) * 1991-02-26 1992-09-02 Bayer Corporation Hybridomas and monoclonal antibodies that inhibit anti-CD3-stimulated T cell proliferation
WO1993004695A1 (en) * 1991-08-28 1993-03-18 The Wistar Institute T cell receptor-based therapy for rheumatoid arthritis
US20040151694A1 (en) * 1994-04-12 2004-08-05 Staley Brod Method of treating auto-immune diseases using type one interferons
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
WO1998030586A2 (en) * 1997-01-13 1998-07-16 Oklahoma Medical Research Foundation Diagnostics and therapy of epstein-barr virus in autoimmune disorders
WO2000067796A1 (en) * 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
WO2001037868A1 (en) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
WO2001058481A2 (en) * 2000-02-09 2001-08-16 Oklahoma Medical Research Foundation Diagnostics and therapy of epstein-barr virus in autoimmune disorders
US20030148963A1 (en) * 2000-05-31 2003-08-07 Andrej Tarkowski Use of etoposide
WO2002047720A2 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders
WO2003025541A2 (en) * 2001-09-18 2003-03-27 Chiron Corporation Methods for treating multiple sclerosis
WO2003028753A1 (en) * 2001-09-29 2003-04-10 Andreas Schwarting USE OF INTERFERON β IN THE THERAPY OF SYSTEMIC LUPUS ERYTHEMATODES
WO2003045978A2 (en) * 2001-11-26 2003-06-05 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
WO2004004798A2 (en) * 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
WO2004032828A2 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20060240008A1 (en) * 2003-04-09 2006-10-26 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
WO2005009466A1 (en) * 2003-07-24 2005-02-03 Universita' Degli Studi Di Perugia Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
US20060257363A1 (en) * 2004-03-10 2006-11-16 Pepgen Corporation Treatment using an interferon
WO2005117978A2 (en) * 2004-06-04 2005-12-15 Genentech, Inc. Method for treating multiple sclerosis
WO2006076651A2 (en) * 2005-01-13 2006-07-20 Genentech, Inc. Treatment method
WO2007014238A2 (en) * 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CROSS A H ET AL: "Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 180, no. 1-2, 1 November 2006 (2006-11-01), pages 63 - 70, XP025039481, ISSN: 0165-5728, [retrieved on 20061101] *
DATABASE WPI Week 199422, Derwent World Patents Index; AN 1994-178486, XP002524094 *
FRIEDMAN J E ET AL: "A randomized clinical trial of valacyclovir in multiple sclerosis.", MULTIPLE SCLEROSIS (HOUNDMILLS, BASINGSTOKE, ENGLAND) JUN 2005, vol. 11, no. 3, June 2005 (2005-06-01), pages 286 - 295, XP009105819, ISSN: 1352-4585 *
HAAHR SVEN ET AL: "Multiple sclerosis is linked to Epstein-Barr virus infection", REVIEWS IN MEDICAL VIROLOGY, vol. 16, no. 5, September 2006 (2006-09-01), pages 297 - 310, XP002524093, ISSN: 1052-9276 *
HARRISON ET AL: "ACYCLOVIR IN RHEUMATOID ARTHRITIS", JOURNAL OF RHEUMATOLOGY, TORONTO, CA, vol. 20, 1 January 1993 (1993-01-01), pages 761/762, XP000881431, ISSN: 0315-162X *
LYCKE J ET AL: "Acyclovir concentrations in serum and cerebrospinal fluid at steady state.", THE JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY DEC 1989, vol. 24, no. 6, December 1989 (1989-12-01), pages 947 - 954, XP009105821, ISSN: 0305-7453 *
LYCKE JAN ET AL: "Acyclovir treatment of relapsing-remitting multiple sclerosis: A randomized, placebo-controlled, double-blind study", JOURNAL OF NEUROLOGY, vol. 243, no. 3, 1996, pages 214 - 224, XP009105820, ISSN: 0340-5354 *
SIBILIA ET AL: "Treatment of systemic lupus erythematosus in 2006", JOINT BONE SPINE, ELSEVIER, PARIS, FR, vol. 73, no. 6, 19 December 2006 (2006-12-19), pages 591 - 598, XP005808730, ISSN: 1297-319X *

Also Published As

Publication number Publication date
WO2008125366A2 (en) 2008-10-23
GB0707208D0 (en) 2007-05-23

Similar Documents

Publication Publication Date Title
WO2008125366A3 (en) Treatment of autoimmune diseases
JP2022088411A5 (en)
MX2010003561A (en) Aspiration system for removing liquid other than urine and discharged by the human body.
EG24202A (en) Disposable absorbent articles being adaptable to wearer's anatomy
WO2004107956A3 (en) Methods and devices for the treatment of skin lesions
EP1594512A4 (en) Compounds for the treatment of viral infection
WO2009148961A3 (en) Drugs to prevent hpv infection
EP2609923A3 (en) Nucleoside Phosphoramidates
AU2003249977A1 (en) Imidazole compounds for the treatment of hepatitis c virus infections
IL178094A0 (en) Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions
PT1711530E (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
EP1741439A4 (en) Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method
WO2009024834A8 (en) Nucleic acids involved in viral infection
WO2008137780A3 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
WO2005002526A3 (en) Method and compositions for treatment of viral infections
EP1765330A4 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
IL202351A (en) Substituted (2-oxo-1,3-oxazolidin-5-yl)methyl-thiophene-2-carboxamides, process for preparing same and use thereof for preparing medicaments for the treatment and/or prophylaxis of diseases
AU2975697A (en) Human monoclonal antibodies to the hepatitis b surface antigen
HU0600190D0 (en) Beehive for elimination of small hive beetle's infection and process to prevent swarming with use of pivotal framed beehive
EP1670507A4 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2003053360A3 (en) Treatment of ebv and khsv infection and associated abnormal cellular proliferation
WO2004066942A3 (en) Purification and uses of dendritic cells and monocytes
EP1827475A4 (en) Method for treatment of hiv infection
WO2002029074A3 (en) Genetic immunisation against cervical carcinoma
JP2011529886A5 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08759309

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08759309

Country of ref document: EP

Kind code of ref document: A2